Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
The pharmaceutical and life sciences sector is changing fast. AI is accelerating drug discovery. Automation is reshaping the lab. Sustainability is no longer optional. This event puts you at the centre of it all.
About the role:
The Policy Lead plays a key role in leading the execution of the Institute’s external genomic policy positions and internal policy development to ensure that Sanger’s science informs national and global decision-making.
Working within the Strategy team, the role translates analysis into targeted policy engagement activity, while strengthening research culture, good research practice, and institutional positioning across government, funders, and international forums.
Your role
We are looking to recruit an expert structural biologist with an experimental background to join the EMDB as a biocurator within the EMBL-EBI OneDep data curation team.
Do you want to help us improve human health and understand life on Earth? Make your mark by shaping the future to enable or deliver life-changing science to solve some of humanity’s greatest challenges.
We are seeking a Director of Operations and Strategy to lead the operational and strategic development of the HDR UK Cambridge partnership, working closely with the Director and senior scientific leadership team to shape and deliver its scientific agenda.
ABOUT DOMAINEX
Founded in 2001 and based near Cambridge, UK, Domainex is an award-winning, independent drug discovery services company. We partner with pharmaceutical, biotechnology, academic and patient foundation groups worldwide to advance the discovery of clinical drug candidates. Our fully integrated capabilities span disease target protein expression and structural biology, assay development, hit discovery, medicinal chemistry, ADME, bioanalytical chemistry and pharmacology, delivering excellence and innovation across the entire drug discovery value chain.
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
• Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action
• Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour types
• Transaction valued at up to $1.5 billion including $1.1 billion cash upfront
Cambridge UK: 03 July 2026
Informa Connect has renewed its partnership with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
An advanced two-day programme for in-house counsel: navigating law, incident response and frontline intelligence
Developed and delivered jointly by Mandiant’s (part of Google Cloud) world‑leading incident response and threat intelligence experts together with senior legal specialists from Marks & Clerk, this two‑day advanced programme provides an academic‑grade, practice‑oriented training experience for in‑house lawyers, general counsel, risk leaders and compliance professionals.